Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 124,950 shares of its common stock and an aggregate of 84,725 restricted stock unit awards to 26 new non-executive employees.

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly


Crinetics announces European Medicines Agency Validation of Marketing Authorization Application and Orphan Drug Designation for paltusotine in acromegaly.

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 95,675 shares of its common stock to fifteen new non-executive employees and 80,000 to one new executive employee.

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update


Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update.

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer


Crinetics company announces the appointment of Tobin Schilke as chief financial officer, effective February 28, 2025.